Acuitas Scientists Co-Author Nature Article
Acuitas Therapeutics’ Chief Scientific Officer, Dr. Ying Tam, and Director of Formulation Development, Paulo Lin, co-authored (with several other scientists) a study titled “Molecular fate-mapping of serum antibody responses to repeat immunization” that was recently published in Nature. Please click
Acuitas Therapeutics Video Update
Acuitas Therapeutics is the global leader in the field of lipid nanotechnology. We specialize in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP). We work with partners to develop new therapies to address unmet